Guowei Fang
Chief Tech/Sci/R&D Officer chez LEGEND BIOTECH CORPORATION
Profil
Guo Wei Fang is currently the Chief Scientific Officer at Legend Biotech Corp.
Prior to this, he held the position of Head-Discovery at Pharmacyclics LLC and Senior Vice President-Research at Zymeworks BC, Inc. He completed his undergraduate degree at Nanjing University and obtained his doctorate from the University of Colorado Boulder.
Postes actifs de Guowei Fang
| Sociétés | Poste | Début |
|---|---|---|
| LEGEND BIOTECH CORPORATION | Chief Tech/Sci/R&D Officer | 01/03/2022 |
Anciens postes connus de Guowei Fang
| Sociétés | Poste | Fin |
|---|---|---|
| PHARMACYCLICS, INC. | Corporate Officer/Principal | - |
Zymeworks BC, Inc.
 Zymeworks BC, Inc. BiotechnologyHealth Technology Zymeworks BC, Inc. is a clinical-stage biopharmaceutical company engaged in the discovery, development, and commercialization of biotherapeutics. Its product, ZW25 and ZW49, are a bispecific antibody that cans two non-overlapping epitopes. The company was founded by Anthony Fejes, J. Haig deB Farris, Nick Bedford, Ali Tehrani and Andrew S. Wright on September 8, 2003 and is headquartered in Vancouver, Canada. | Chief Tech/Sci/R&D Officer | - |
Formation de Guowei Fang
| Nanjing University | Undergraduate Degree |
| University of Colorado Boulder | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| LEGEND BIOTECH CORPORATION | Health Technology |
| Entreprise privées | 2 |
|---|---|
Pharmacyclics LLC
 Pharmacyclics LLC Pharmaceuticals: MajorHealth Technology Pharmacyclics LLC engages in developing and commercializing innovative small-molecule drugs for the treatment of cancer and immune mediated diseases. It has product candidates in clinical development and several preclinical molecules in optimization. The company was founded by Jonathan Sessler and Richard Miller in 1991 and is headquartered in Sunnyvale, CA. | Health Technology |
Zymeworks BC, Inc.
Zymeworks BC, Inc. BiotechnologyHealth Technology Zymeworks BC, Inc. is a clinical-stage biopharmaceutical company engaged in the discovery, development, and commercialization of biotherapeutics. Its product, ZW25 and ZW49, are a bispecific antibody that cans two non-overlapping epitopes. The company was founded by Anthony Fejes, J. Haig deB Farris, Nick Bedford, Ali Tehrani and Andrew S. Wright on September 8, 2003 and is headquartered in Vancouver, Canada. | Health Technology |
